Italian Multicenter Study on Accuracy of 18F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma

Angelina Cistaro, Laura Cassalia, Cinzia Ferrara, Natale Quartuccio, Laura Evangelista, Maurizio Bianchi, Franca Fagioli, Gianni Bisi, Sergio Baldari, Alessandro Zanella, Marta Pillon, Pietro Zucchetta, Marta Burei, Alessandra Sala, Luca Guerra, Priscilla Guglielmo, Roberta Burnelli, Stefano Panareo, Federica Scalorbi, Ilaria RambaldiArnoldo Piccardo, Alberto Garaventa, Demetrio Familiari, Maria Concetta Fornito, Egesta Lopci, Maurizio Mascarin, Corinna Altini, Cristina Ferrari, Teresa Perillo, Nicola Santoro, Eugenio Borsatti, Giuseppe Rubini

Research output: Contribution to journalArticle

Abstract

The present study investigated the utility of fluorine-18 (18F) fluoro-2-deoxy-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared with bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin lymphoma (HL). 18F-FDG PET/CT shows high diagnostic performance in evaluating BMI in pediatric HL. BMB should be ideally reserved for patients with doubtful 18F-FDG PET/CT BMI findings. Introduction: The present study investigated the utility of fluorine-18 (18F) fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in assessing bone marrow involvement (BMI) compared with bone marrow biopsy (BMB) in newly diagnosed pediatric Hodgkin lymphoma (HL). Patients and Methods: A total of 224 pediatric patients with HL underwent 18F-FDG PET/CT at staging. BMB or follow-up imaging was used as the standard of reference for the evaluation of BMI. Results: 18F-FDG PET/CT was negative for BMI in 193 cases. Of the 193 patients, the findings for 16 were originally reported as doubtful and later interpreted as negative for BMI, with negative findings on follow-up imaging and BMB. At BMB, 1 of the 16 patients (6.25%) had BMI. Of the 193 patients, 192 (99.48%) had negative BMB findings. Thus, the 18F-FDG PET/CT findings were truly negative for 192 patients and falsely negative for 1 patient for BMI. Conclusion: 18F-FDG PET/CT showed high diagnostic performance in the evaluation of BMI in pediatric HL. Thus, BMB should be ideally reserved for patients presenting with doubtful 18F-FDG PET/CT findings for BMI.

Original languageEnglish
Pages (from-to)e267-e273
JournalClinical Lymphoma, Myeloma and Leukemia
Volume18
Issue number6
DOIs
Publication statusPublished - Jun 1 2018

Keywords

  • BMI
  • Bone marrow biopsy
  • Computed tomography
  • Newly diagnosed pediatric HL
  • Positron emission tomography

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Italian Multicenter Study on Accuracy of <sup>18</sup>F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Cistaro, A., Cassalia, L., Ferrara, C., Quartuccio, N., Evangelista, L., Bianchi, M., Fagioli, F., Bisi, G., Baldari, S., Zanella, A., Pillon, M., Zucchetta, P., Burei, M., Sala, A., Guerra, L., Guglielmo, P., Burnelli, R., Panareo, S., Scalorbi, F., ... Rubini, G. (2018). Italian Multicenter Study on Accuracy of 18F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 18(6), e267-e273. https://doi.org/10.1016/j.clml.2018.04.002